The CMTA Inherited Neuropathy Consortium Alliance (CMTA-INC) has enrolled its 10,000th patient, marking a major milestone in the search for treatments...
FDA to Hold Patient Listening Session for CMT2C/TRPV4
This October, the FDA will host a Patient Listening Session for the CMT2C/TRPV4 community, organized by CMTA. During this event, the FDA will hear from people living with this form of CMT about their lives, their needs, and their hopes for new treatments.
How the CMT2C Community Is Driving the Path to Treatment
How is the CMT2C community helping move research forward? A CMTA-hosted focus group on how patient voices are shaping the path to a treatment.
Actio Biosciences – ABS-0871
The Phase I study is a randomized, double-blind, placebo-controlled trial evaluating the safety, tolerability, and...
Actio Biosciences Doses First Participant in Phase I Trial
CMTA-STAR Alliance Partner Actio Biosciences has announced that the first participant has been dosed in its Phase...
